190 related articles for article (PubMed ID: 21856265)
1. Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Szturz P; Adam Z; Klincová M; Feit J; Krejčí M; Pour L; Zahradová L; Vašků V; Hájek R; Mayer J
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):517-20. PubMed ID: 21856265
[No Abstract] [Full Text] [Related]
2. [IgA pemphigus accompanying multiple myeloma].
Veselý K
Vnitr Lek; 2009 Oct; 55(10):915-6. PubMed ID: 19947233
[No Abstract] [Full Text] [Related]
3. [IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Adam Z; Feit J; Krejcí M; Pour L; Vasků V; Cermáková Z; Mayer J; Hájek R
Vnitr Lek; 2009 Oct; 55(10):981-90. PubMed ID: 19947244
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
5. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
6. IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.
Adam Z; Krejcí M; Pour L; Feit J; Büchler T; Hájek R
Wien Klin Wochenschr; 2010 May; 122(9-10):311-4. PubMed ID: 20559888
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
8. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
9. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Baz R; Miladinovic B; Patel A; Ho VQ; Shain KH; Alsina M; Nishihori T; Ochoa-Bayona JL; Sullivan DM; Dalton WS; Djulbegovic B
Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for relapsed and refractory multiple myeloma.
Lonial S; Mitsiades CS; Richardson PG
Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
[TBL] [Abstract][Full Text] [Related]
11. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Chim CS
Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
[No Abstract] [Full Text] [Related]
12. The role of novel drugs in multiple myeloma.
Dimopoulos MA; Kastritis E
Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953
[No Abstract] [Full Text] [Related]
13. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
14. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
[No Abstract] [Full Text] [Related]
15. "IM iD"eally treating multiple myeloma.
Lacy MQ
Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Takeda Y; Sakaida E; Nakaseko C
Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
[TBL] [Abstract][Full Text] [Related]
17. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Chanan-Khan A; Miller KC
Leuk Lymphoma; 2005 Jul; 46(7):1103-4. PubMed ID: 16019567
[No Abstract] [Full Text] [Related]
18. [A rare cause of hyperamylasemia].
Nafil H; Tazi I; Mahmal L
Ann Biol Clin (Paris); 2012; 70(2):237-8. PubMed ID: 22484539
[No Abstract] [Full Text] [Related]
19. Novel approaches to the management of myeloma.
Rajkumar SV
Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290
[TBL] [Abstract][Full Text] [Related]
20. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]